ESH 2017 | Upcoming clinical trials for venetoclax chemotherapy combinations for AML

Marina Konopleva

This is an exciting time for new acute myeloid leukemia (AML) therapies, particularly combination treatments. In this video, Marina Konopleva, MD, PhD of the MD Anderson Cancer Center, Houston, TX, discusses planned upcoming clinical trials for new venetoclax chemotherapy combinations for AML, including that with FLAG-IDA (NCT03214562). Dr Konopleva explains why she is hopeful that these regimens will improve treatment and mentions the combination therapies that she hopes to work on in the future. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).

Share this video